ERCC2 and cancer: The present investigation showed that higher ERCC2 expression was associated with poor patient survival (Figure 3A), and ERCC2 protein levels can be markedly higher in cancer vs. normal tissue (Figure 3B), implying that drugs that target ERCC2 for downregulation are likely to have broader safety and therapeutic efficacy.